165 related articles for article (PubMed ID: 11162843)
1. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.
Spenlehauer C; Gordon CA; Trkola A; Moore JP
Virology; 2001 Feb; 280(2):292-300. PubMed ID: 11162843
[TBL] [Abstract][Full Text] [Related]
2. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.
Trkola A; Matthews J; Gordon C; Ketas T; Moore JP
J Virol; 1999 Nov; 73(11):8966-74. PubMed ID: 10516002
[TBL] [Abstract][Full Text] [Related]
3. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
Miyake H; Iizawa Y; Baba M
J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
[TBL] [Abstract][Full Text] [Related]
4. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.
Chiba-Mizutani T; Miura H; Matsuda M; Matsuda Z; Yokomaku Y; Miyauchi K; Nishizawa M; Yamamoto N; Sugiura W
J Clin Microbiol; 2007 Feb; 45(2):477-87. PubMed ID: 17182760
[TBL] [Abstract][Full Text] [Related]
5. A potential in vitro and in vivo anti-HIV drug screening system for Chinese herbal medicines.
Feng L; Wang L; Ma YY; Li M; Zhao GQ
Phytother Res; 2012 Jun; 26(6):899-907. PubMed ID: 22852142
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
7. A novel dual-luciferase assay for anti-HIV drug screening based on the CCR5/CXCR4 promoters.
Feng L; Lu W; Ma Y; Guo W; Wang Y; Sun Q; Wu J; Zhao G; Zhang X
J Virol Methods; 2018 Jun; 256():17-23. PubMed ID: 29481882
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
[TBL] [Abstract][Full Text] [Related]
9. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.
Ochsenbauer-Jambor C; Jones J; Heil M; Zammit KP; Kutsch O
Biotechniques; 2006 Jan; 40(1):91-100. PubMed ID: 16454046
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.
Baba M; Miyake H; Okamoto M; Iizawa Y; Okonogi K
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):935-41. PubMed ID: 10890354
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds.
Owen SM; Rudolph D; Schols D; Fujii N; Yamamoto N; Lal RB
J Med Virol; 2002 Oct; 68(2):147-55. PubMed ID: 12210401
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.
Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
Retrovirology; 2004 Mar; 1():2. PubMed ID: 15169555
[TBL] [Abstract][Full Text] [Related]
13. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
Pontow S; Ratner L
J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
[TBL] [Abstract][Full Text] [Related]
14. Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.
Sloan RD; Donahue DA; Kuhl BD; Bar-Magen T; Wainberg MA
Retrovirology; 2010 May; 7():44. PubMed ID: 20465832
[TBL] [Abstract][Full Text] [Related]
15. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
17. A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses.
Kajiwara K; Kodama E; Matsuoka M
Antivir Chem Chemother; 2006; 17(4):215-23. PubMed ID: 17066899
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
19. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains.
Huang L; Bosch I; Hofmann W; Sodroski J; Pardee AB
J Virol; 1998 Nov; 72(11):8952-60. PubMed ID: 9765440
[TBL] [Abstract][Full Text] [Related]
20. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120.
Maeda Y; Yusa K; Harada S
Antiviral Res; 2008 Feb; 77(2):128-35. PubMed ID: 18160142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
